Disorders of glycoprotein metabolism

E4_GLYCOPROT

No definition available.

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps	FinnGen
Phenotype data	519972
1. Apply sex-specific rule None	519972
2. Check conditions None	519972
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — E77 Cause of death: ICD-10 — E77 2 out of 7 registries used, show all original rules.	42
4. Check minimum number of events None	42
5. Include endpoints E4_LYSOPOSTTRANS E4_GLYCOPROTDEGR E4_GLYCOPROTNAS	42
6. Filter based on genotype QC (FinnGen only)	40

Control definitions (FinnGen only)

Control exclude: E4_METABOLIA

Extra metadata

Level in the ICD hierarchy: 3
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: E70-E90
Name in latin: Perturbationes metabolismi glycoproteinorum

NAME	E4_GLYCOPROT
CONTROL_EXCLUDE	E4_METABOLIA
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE	E4_LYSOPOSTTRANS\|E4_GLYCOPROTDEGR\|E4_GLYCOPROTNAS
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	E77
HD_ICD_9
HD_ICD_8
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	E77
COD_ICD_9
COD_ICD_8
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Disorders of glycoprotein metabolism based on the number of shared cases.

Similar with more cases:

Similar with less cases:

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	490	243	246
Only index persons	390	191	199
Unadjusted period prevalence (%)
Whole population	0.01	0.01	0.01
Only index persons	0.01	0.01	0.01
Median age at first event (years)
Whole population	39.76	40.27	39.07
Only index persons	38.47	38.07	38.86

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	40	22	18
Unadjusted period prevalence (%)	0.01	0.01	0.01
Median age at first event (years)	51.90	52.13	51.61

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

No data available

LabWAS

↥

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(3000330) Specific gravity of Urine by Test strip

14.08

6.17

3.0

2.1

—

(3013512) EKG study

4.60

5.58

6.7

2.5

—

(3004383) Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence

16.36

4.75

1.0

1.4

—

(3009445) Proteinase 3 Ab [Units/volume] in Serum

9.55

4.27

1.0

1.3

—

(4094501) Cardiovascular stress test using bicycle ergometer

8.67

4.07

1.3

1.2

—

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

101

3.47

3.80

2.0

1.8

95.27

102.19

pmol/l

0.22

(3004529) Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood

11.37

3.61

4.8

3.3

65.25

47.80

—

(3018010) Neutrophils/100 leukocytes in Blood

168

3.35

3.28

8.1

5.1

51.87

53.54

0.42

158

(3041096) Erythrocytes [Presence] in Urine by Automated

3.16

3.19

4.1

2.1

—

(1761868) Lipid panel - Serum or Plasma

111

3.06

3.11

4.5

2.3

—

(3002030) Lymphocytes/100 leukocytes in Blood

173

3.18

3.03

8.2

5.1

33.48

31.61

0.47

162

(3016431) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma

150

2.92

2.81

17.3

5.2

1.22

mmol/l

0.07

127

(3021589) Normoblasts [#/volume] in Blood

159

2.95

2.81

11.4

7.9

0.00

e9/l

-0.00

125

(3029187) Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma

2.97

2.70

2.1

2.3

782.00

548.88

ng/l

0.26

(3005895) Myoglobin [Mass/volume] in Serum or Plasma

7.90

2.62

4.2

1.1

120.80

227.96

ug/l

—

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

5.02

2.60

1.6

1.3

—

(3009035) Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma

3.17

2.53

2.4

1.8

433.67

481.70

pmol/l

0.45

(3024561) Albumin [Mass/volume] in Serum or Plasma

123

2.66

2.43

7.7

4.1

36.15

36.37

g/l

0.08

115

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

124

2.63

2.38

4.2

2.7

—

(3007853) Bacteria identified in Skin by Aerobe culture

3.32

2.33

2.4

1.4

—

(3021960) Folate [Moles/volume] in Serum or Plasma

2.91

2.33

1.5

25.36

23.48

nmol/l

0.11

(3019198) Lymphocytes [#/volume] in Blood

183

2.59

2.16

8.1

5.2

2.24

2.55

e9/l

0.23

165

(3019150) Specific gravity of Urine by Refractometry

2.59

1.98

3.2

1.01

1.02

kg/l

—

(3013721) Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma

117

2.35

1.90

3.0

38.25

30.95

u/l

1.03

111

(21494755) Public health laboratory ask at order entry panel

0.00

1.84

0.0

1.4

—

(3010517) Carboxyhemoglobin/Hemoglobin.total in Venous blood

4.21

1.77

7.8

3.8

1.26

0.97

—

(3006504) Eosinophils/100 leukocytes in Blood

166

2.25

1.72

8.1

5.2

3.60

2.94

0.62

154

(3019069) Monocytes/100 leukocytes in Blood

167

2.23

1.68

8.2

5.4

8.44

8.32

0.07

157

(3015736) pH of Urine

122

2.22

1.68

4.0

2.6

—

5.82

—

(3022096) Basophils/100 leukocytes in Blood

158

2.21

1.67

8.4

5.2

0.88

0.65

1.73

144

(3008152) Bicarbonate [Moles/volume] in Arterial blood

3.90

1.66

8.6

7.4

25.36

26.53

mmol/l

—

(3019060) Gas panel - Arterial blood

3.63

1.57

8.0

4.7

—

(40771025) 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma

129

2.05

1.41

3.3

2.2

78.60

78.30

nmol/l

0.02

119

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

3.19

1.40

1.8

1.2

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

112

2.06

1.39

4.5

2.6

—

(36304419) Bacteria [Presence] in Urine

2.10

1.34

3.3

2.2

—

(3022621) pH of Urine by Test strip

2.63

1.29

2.5

2.0

—

(3022217) INR in Platelet poor plasma by Coagulation assay

133

1.96

1.26

19.4

7.6

1.57

1.18

inr

—

(3026008) Bacteria identified in Urine by Culture

2.03

1.15

1.8

2.5

—

(3006315) Basophils [#/volume] in Blood

174

1.89

1.14

8.1

5.3

0.05

0.04

e9/l

1.03

150

(3001604) Monocytes [#/volume] in Blood

175

1.87

1.11

8.0

5.3

0.60

0.54

e9/l

0.54

151

(3023368) Bacteria identified in Blood by Culture

2.03

1.11

7.2

3.3

—

(40760892) CBC W Ordered Manual Differential panel - Blood

166

1.85

1.10

10.9

5.9

—

(3048689) Calprotectin [Mass/mass] in Stool

2.06

1.07

2.7

2.1

167.44

63.90

ug/g

—

(3015399) Transferrin receptor.soluble [Mass/volume] in Serum or Plasma

2.05

1.06

2.5

2.4

3.65

2.98

mg/l

0.43

(43055554) Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation

2.44

1.06

4.8

3.6

1.66

1.92

mmol/l

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

161

1.77

0.97

2.4

2.6

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

2.01

0.92

1.7

1.5

—

(3037467) Urinalysis macro (dipstick) panel - Urine

227

1.70

0.80

4.3

3.1

—

(40768804) Tissue Pathology biopsy report

135

0.58

0.78

3.9

1.8

—

(3042936) Bacteria identified in Isolate by Culture

1.90

0.76

1.9

1.7

—

(3007220) Creatine kinase [Enzymatic activity/volume] in Serum or Plasma

1.72

0.74

4.3

1.8

630.92

124.72

u/l

0.48

(3025839) Triglyceride [Moles/volume] in Serum or Plasma

100

0.53

0.74

1.5

1.6

1.91

1.24

mmol/l

—

(3027946) Carbon dioxide [Partial pressure] in Arterial blood

1.89

0.68

2.2

6.0

5.00

5.30

kpa

—

(3001019) Free T4 and TSH panel - Serum or Plasma

0.00

0.60

0.0

1.3

—

(3022145) Colonoscopy Study observation

1.72

0.58

1.3

1.2

—

(3006140) Bilirubin.total [Moles/volume] in Serum or Plasma

177

1.51

0.58

6.5

5.5

21.18

13.48

umol/l

0.33

167

(3017143) Hepatitis C virus Ab [Presence] in Serum

1.63

0.55

3.5

1.4

—

(3019309) Folate [Moles/volume] in Red Blood Cells

1.62

0.51

2.4

1.4

1236.57

1288.41

nmol/l

—

(3001122) Ferritin [Mass/volume] in Serum or Plasma

132

1.48

0.51

5.2

2.3

106.18

87.41

ug/l

0.20

121

(3035995) Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma

261

1.52

0.51

13.6

6.4

96.23

84.59

u/l

0.67

242

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

1.64

0.44

1.4

1.5

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

1.58

0.43

1.4

1.5

—

(3000991) Gas panel - Venous blood

1.58

0.43

5.4

4.9

—

(3013650) Neutrophils [#/volume] in Blood by Automated count

215

1.40

0.41

9.8

9.0

3.57

3.66

e9/l

0.11

184

(3013603) Prostate specific Ag [Mass/volume] in Serum or Plasma

1.43

0.37

8.2

4.8

14.01

1.81

ug/l

0.48

(3000494) Fungus identified in Specimen by Culture

1.46

0.37

1.8

1.4

—

(3044640) Blood type and Crossmatch panel - Blood

102

1.40

0.35

2.2

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

1.41

0.33

3.4

1.6

—

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

1.36

0.24

1.2

1.5

—

(3003031) Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma

1.32

0.22

1.8

1.5

2.60

1.41

—

(3050380) Cytology report of Cervical or vaginal smear or scraping Cyto stain

0.00

0.21

0.0

1.4

—

(3006418) Campylobacter sp identified in Tissue by Organism specific culture

0.00

0.21

0.0

1.4

—

(44816559) Phosphatidylethanol [Mass/volume] in Blood

0.00

0.21

0.0

1.4

—

(1001926) Buprenorphine [Presence] in Urine by Screen method

0.00

0.21

0.0

1.2

—

(3029511) Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection

0.00

0.21

0.0

1.4

—

(3024891) Influenza virus A+B Ag [Presence] in Specimen

0.00

0.21

0.0

1.1

—

(40766189) Gliadin peptide IgG Ab [Units/volume] in Serum by Immunoassay

0.00

0.21

0.0

1.1

—

(3017766) Complement C4 [Mass/volume] in Serum or Plasma

0.00

0.21

0.0

1.2

—

0.22

—

(3000620) Complement C3 [Mass/volume] in Serum or Plasma

0.00

0.20

0.0

1.2

—

1.19

—

(3003694) ABO and Rh group [Type] in Blood

101

1.26

0.19

1.3

1.5

—

(3026910) Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma

220

1.21

0.17

4.6

3.0

97.83

42.62

u/l

1.84

209

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

1.25

0.15

2.1

2.3

—

(3015377) Calcium [Moles/volume] in Serum or Plasma

104

0.83

0.15

5.6

2.9

2.33

2.37

mmol/l

—

(3013707) Erythrocyte sedimentation rate by Westergren method

255

1.16

0.11

7.7

3.7

16.74

9.72

mm/h

1.37

232

(46235355) HIV 1 and 2 tests - Meaningful Use set

1.08

0.09

3.7

1.6

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

1.06

0.08

2.1

3.1

—

(3021347) Calcium.ionized [Moles/volume] in Serum or Plasma

140

1.11

0.05

17.5

5.2

1.18

1.22

mmol/l

1.03

129

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

232

1.08

0.03

3.2

3.1

—

(3009201) Thyrotropin [Units/volume] in Serum or Plasma

326

0.92

0.01

6.3

4.2

1.76

1.85

mu/l

0.18

297

(3044889) 12 lead EKG panel

239

1.01

0.00

3.2

3.4

—

(3020321) Streptococcus agalactiae [Presence] in Vaginal fluid by Organism specific culture

0.00

-0.00

0.0

1.2

—

(3029338) Protein.monoclonal band 3 [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

-0.00

0.0

5.4

—

0.00

—

(3042111) Morphology [Interpretation] in Bone marrow Narrative

0.00

-0.00

0.0

2.0

—

(3047826) Mullerian inhibiting substance [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

1.2

—

4.70

—

(3002523) Influenza virus A Ag [Presence] in Specimen

0.00

-0.00

0.0

1.1

—

(4281824) Cell count and differential, peritoneal fluid

0.00

-0.00

0.0

1.0

—

(3050129) First trimester maternal screen panel - Serum or Plasma

0.00

-0.00

0.0

1.8

—

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

0.96

-0.00

1.2

1.3

—

(3006588) Cancer Ag 15-3 [Units/volume] in Serum or Plasma

0.00

-0.00

0.0

2.3

—

17.79

—

(3013201) Beta-2-Microglobulin [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

1.2

—

5.40

—

(3016881) Enterovirus RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.3

—

(3029379) Protein.monoclonal band 4 [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

-0.00

0.0

5.4

—

0.00

—

(21494670) JAK2 gene exon 14 targeted mutation analysis in Blood or Tissue by Molecular genetics method

0.00

-0.00

0.0

1.2

—

(3003265) Liver kidney microsomal Ab [Titer] in Serum by Immunofluorescence

0.00

-0.00

0.0

1.1

—

(3028707) Methadone [Presence] in Urine by Screen method

0.00

-0.00

0.0

1.4

—

(3032773) Endomysium IgG Ab [Titer] in Serum

0.00

-0.00

0.0

1.0

—

(3026179) Normetanephrine [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.2

—

0.30

—

(3025023) Rhinovirus RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.4

—

(3009340) Metanephrine [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.2

—

(3016407) Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay

0.00

-0.00

0.0

1.4

—

2.76

—

(3035797) Protein.monoclonal band 2 [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

-0.00

0.0

5.1

—

0.00

—

(46235689) Lupus anticoagulant aPTT, dRVVT and PT screening panel W Reflex

0.00

-0.00

0.0

1.6

—

(3005013) Prostate Specific Ag Free [Mass/volume] in Serum or Plasma

0.90

-0.00

4.8

3.0

1.81

0.61

ug/l

—

(3000855) Microscopic observation [Identifier] in Vaginal fluid by Gram stain

0.00

-0.00

0.0

2.7

—

(40758558) Short blood count panel - Blood

0.95

-0.00

6.7

5.8

—

(3008909) Norovirus RNA [Presence] in Stool by NAA with probe detection

0.00

-0.00

0.0

1.0

—

(40768800) Prostate Pathology biopsy report

0.00

-0.00

0.0

1.0

—

(21494434) Karyotype in Bone marrow

0.00

-0.00

0.0

1.0

—

(1002102) Choriogonadotropin.intact+Beta subunit [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

1.2

—

(3003740) Influenza virus B Ag [Presence] in Specimen

0.00

-0.00

0.0

1.1

—

(3048821) Cortisol [Moles/volume] in Serum or Plasma --post 1 mg dexamethasone PO overnight

0.00

-0.00

0.0

1.3

—

(3011288) Drugs identified in Urine by Screen method

0.00

-0.00

0.0

1.6

—

(3012202) Varicella zoster virus DNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.0

—

(3030408) 3-Methoxytyramine [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.2

—

(40768797) Stomach Pathology biopsy report

1.02

-0.00

1.2

—

(44816844) Macroprolactin [Units/volume] in Serum or Plasma

0.00

-0.00

0.0

1.0

—

(42529200) Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay

0.00

-0.00

0.0

2.2

—

15.60

—

(3039443) Prostate specific Ag panel - Serum or Plasma

0.00

-0.00

0.0

1.7

—

(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay

0.00

-0.00

0.0

1.0

—

(3000924) Streptococcus pyogenes [Presence] in Throat by Organism specific culture

0.00

-0.00

0.0

1.2

—

Mortality – FinRegistry

↥

Association

Association between endpoint E4_GLYCOPROT and mortality.

Females

No data

Males

Parameter	HR [95% CI]	p-value
E4_GLYCOPROT	5.737 [3.32, 9.92]	< 0.001
Birth year	0.985 [0.98, 0.99]	0.003

During the follow-up period (1.1.1998 — 31.12.2019), 64 out of 195 males with E4_GLYCOPROT died.

Mortality risk

Mortality risk for people of age

years, who have E4_GLYCOPROT.

N-year risk	Females	Males
1	No data	0.985%
5	No data	5.653%
10	No data	14.629%
15	No data	26.381%
20	No data	40.026%

Relationships between endpoints

↥

Index endpoint: E4_GLYCOPROT – Disorders of glycoprotein metabolism

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Disorders of glycoprotein metabolism

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints